Goldman Sachs Group Inc Omega Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$613 Billion
Q4 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.86 - $3.2 $312,552 - $537,724	168,039 Added 761.46%	190,107 $393,000
Q1 2024 May 15, 2024	BUY	$2.73 - $5.32 $24,815 - $48,358	9,090 Added 70.04%	22,068 $80,000
Q4 2023 Feb 13, 2024	SELL	$1.35 - $3.21 $9,315 - $22,149	-6,900 Reduced 34.71%	12,978 $39,000
Q3 2023 May 14, 2024	BUY	$2.15 - $5.68 $14,835 - $39,192	6,900 Added 53.17%	19,878 $42,000
Q3 2023 Nov 14, 2023	BUY	$2.15 - $5.68 $6,011 - $15,881	2,796 Added 16.37%	19,878 $42,000
Q2 2023 May 14, 2024	SELL	$5.6 - $9.66 $191,744 - $330,758	-34,240 Reduced 66.72%	17,082 $95,000
Q2 2023 Aug 14, 2023	SELL	$5.6 - $9.66 $191,744 - $330,758	-34,240 Reduced 66.72%	17,082 $95,000
Q1 2023 May 14, 2024	BUY	$4.81 - $10.95 $167,464 - $381,235	34,816 Added 210.93%	51,322 $309,000
Q1 2023 May 11, 2023	BUY	$4.81 - $10.95 $167,464 - $381,235	34,816 Added 210.93%	51,322 $309,000
Q4 2022 May 14, 2024	SELL	$4.22 - $7.05 $5,376 - $8,981	-1,274 Reduced 7.17%	16,506 $94,000
Q4 2022 Feb 13, 2023	SELL	$4.22 - $7.05 $5,376 - $8,981	-1,274 Reduced 7.17%	16,506 $94,000
Q3 2022 May 14, 2024	SELL	$3.63 - $6.65 $6,519 - $11,943	-1,796 Reduced 9.17%	17,780 $96,000
Q3 2022 Nov 10, 2022	SELL	$3.63 - $6.65 $6,519 - $11,943	-1,796 Reduced 9.17%	17,780 $0
Q2 2022 May 14, 2024	BUY	$2.01 - $7.19 $13,261 - $47,439	6,598 Added 50.84%	19,576 $74,000
Q2 2022 Aug 15, 2022	SELL	$2.01 - $7.19 $3,909 - $13,984	-1,945 Reduced 9.04%	19,576 $74,000
Q1 2022 May 16, 2022	BUY	$6.24 - $14.04 $15,412 - $34,678	2,470 Added 12.97%	21,521 $134,000
Q4 2021 Feb 14, 2022	BUY	$11.33 - $29.38 $215,847 - $559,718	19,051 New	19,051 $216,000

Others Institutions Holding OMGA

# of Institutions

Shares Held

42.6M

Call Options Held

5.9K

Put Options Held

View Full List

About Omega Therapeutics, Inc.

Ticker OMGA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,853,400
Market Cap $11M
Description
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-...

More about OMGA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account